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Abstract
AIM
To evaluate outcome of acute management and risk of 
rebleeding in patients with massive hemorrhage due to 
hepatocellular adenoma (HCA). 
METHODS
This retrospective cohort study included all consecutive 
patients who presented to our hospital with massive 
hemorrhage (grade Ⅱ or Ⅲ) due to ruptured HCA 
and were admitted for observation and/or inter-
vention between 1999-2016. The diagnosis of HCA 
was based on radiological findings from contrast-
enhanced magnetic resonance imaging (MRI) or 
pathological findings from biopsy or resection of the 
HCA. Hemorrhage was diagnosed based on findings 
from computed tomography or MRI. Medical records 
were reviewed for demographic features, clinical 
presentation, tumor features, initial and subsequent 
management, short- and long-term complications and 
patient and lesion follow-up. 
RESULTS
All patients were female (n  = 23). Treatment in 
the acute phase consisted of embolization (n  = 9, 
39.1%), conservative therapy (n  = 13, 56.5%), and 
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other intervention (n  = 1, 4.3%). Median hemoglobin 
level decreased significantly more on days 0-3 in the 
intervention group than in the patients initially treated 
conservatively (0.9 mmol/L vs  2.4 mmol/L respectively, 
P  = 0.006). In total, 4 patients suffered severe short-
term complications, which included hypovolemic shock, 
acute liver failure and abscess formation. After a 
median follow-up of 36 mo, tumor regression in non-
surgically treated patients occurred with a median 
reduction of 76 mm down to 25 mm. Four patients 
underwent secondary (elective) treatment (i.e. , tumor 
resection) to address HCA size of > 5 cm and/or desire 
for future pregnancy. One case of rebleeding was 
documented (4.3%). None of the patients experienced 
long-term complication (mean follow-up time: 36 mo). 
CONCLUSION
With a 4.3% risk of rebleeding, secondary (elective) 
treatment of HCA after massive hemorrhage may only 
be considered in patients with persistent HCA > 5 cm.
Key words: Hepatocellular adenoma; Management; 
Bleeding; Outcome; Hemorrhage
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: As massive bleeding due to ruptured 
hepatocellular adenoma (HCA) is rare, we present 
a unique series of 23 consecutive patients. To our 
knowledge, this is the first study to assess the outcome 
and sequelae of the massive bleeding complication, 
including risk of rebleeding and need for elective tumor 
resection. In our series, risk of rebleeding was 4.3% 
and most HCAs regressed spontaneously. No long-term 
complications were documented. These cases suggest 
that a wait-and-watch policy may be legitimate and 
secondary (elective) treatment may only be considered 
for persistent HCA > 5 cm after follow-up and/or for 
patients with desire for future pregnancy. 
Klompenhouwer AJ, de Man RA, Thomeer MGJ, Ijzermans 
JNM. Management and outcome of hepatocellular adenoma with 
massive bleeding at presentation. World J Gastroenterol 2017; 
23(25): 4579-4586  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v23/i25/4579.htm  DOI: http://dx.doi.
org/10.3748/wjg.v23.i25.4579
INTRODUCTION
Hepatocellular adenoma (HCA) is a rare benign 
liver tumor that occurs mostly in women in their 
reproductive phase. An association with the estrogen-
containing oral contraceptive (OC) was first described 
in 1973[1,2]. Currently, the estimated annual incidences 
are 30-40 per million in long-term (> 2 years) OC 
users and 1 per million in non-users or women with 
less than 2 years of OC use[3]. 
HCAs are most often asymptomatic and discovered 
during radiologic imaging of the abdomen for un-
related reasons. The best way to diagnose HCA is 
with contrast-enhanced magnetic resonance imaging 
(MRI)[4]. In the past decade, much has changed in 
terms of diagnosis and treatment of HCA, due to the 
discovery of various subtypes of this tumor[5,6]. The 
change in treatment strategy is ongoing, due to the 
apparent differences in risks of complications for the 
various subtypes. 
As HCAs are well vascularized tumors, hemorrhage - 
as documented on imaging - is a common complication, 
occurring in approximately 25% of the patients with 
HCA[7]. OC use, tumor size of > 5 cm, exophytic growth 
of the tumor and inflammatory subtype (I-HCA) are 
associated with a higher risk of bleeding[7,8]. Most 
hemorrhages are intratumoral; however, in cases 
of massive bleeding, rupture of the HCA can occur, 
resulting in intraparenchymal hemorrhage and 
subcapsular hematoma. In some cases, the liver 
capsule can rupture, causing hemoperitoneum.
Hemorrhagic HCAs cause symptoms such as acute-
onset right upper abdominal pain and discomfort. 
In cases of tumor rupture and excessive bleeding, 
patients may present with hemodynamically unstable 
conditions and even may show signs of hypovolemic 
shock. This complication can be life threatening[3]. 
Another rare complication of HCAs, not related 
to risk of bleeding, is malignant degeneration to 
hepatocellular carcinoma, which occurs mostly in 
β-catenin-positive HCA[9]. As both hemorrhage and 
malignant degeneration arise especially in adenomas 
> 5 cm in size, surgical resection is recommended 
for HCA which do not regress by 6 mo after cessation 
of OC and following lifestyle changes, such as weight 
reduction in overweight patients[10-13]. 
The management policy for acute bleeding of 
ruptured HCA has changed over the past years. In 
the acute phase, a conservative management and 
hemodynamic stabilization is justified[14]. In case of 
active bleeding with persistent hemodynamic instability 
or hemoperitoneum, intervention may be considered[7]. 
Liver resection in the acute phase is associated with 
increased morbidity and mortality and, therefore, not 
advisable[15]. Laparotomy and gauze packing of the 
liver had been recommended until the introduction 
of minimally-invasive techniques. The advent of 
selective arterial embolization (SAE) 10 years ago 
has now allowed for patients to be treated even less 
invasively[16,17]. An unanswered question, however, 
remains in regards to the chance of rebleeding and, 
correspondingly, the need for elective tumor resection. 
In this study, we evaluated the outcome of acute 
management in patients with massive hemorrhage due 
to ruptured HCA and its sequelae, including the risk of 
rebleeding and need for elective tumor resection.
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MATERIALS AND METHODS
Study design
This study was a retrospective cohort study performed 
in a tertiary referral center for focal liver lesions. With 
the availability of a large HCA cohort, consisting of 449 
patients, we selected all patients who presented with 
massive hemorrhage as a result of ruptured HCA and 
who were admitted to a hospital ward for observation 
and/or intervention between January 1999 (the start 
of the database) and April 2016, with follow-up time of 
at least 6 mo.
This study was approved by the accredited local 
institutional review board (No. MEC-2016-338) and 
informed consent was waived.
Patient selection
Massive hemorrhage was defined as intrahepatic 
(grade Ⅱ) or intraperitoneal (grade Ⅲ), as reported 
by Bieze et al[8] in 2014. Patients with intratumoural 
hemorrhage (grade Ⅰ) were excluded from this study. 
The diagnosis of HCA was based on radiological 
findings from contrast-enhanced magnetic resonance 
imaging (MRI) or pathological findings from biopsy 
or resection of the HCA. Hemorrhage was diagnosed 
based on findings from computed tomography (CT) or 
MRI. Hepatocellular carcinoma - the main competing 
differential diagnosis - was excluded by occurrence 
of tumor regression after hemorrhage, absence of 
progression in diameter and lack of metastatic disease 
over time.
On CT, the density of a hematoma is determined 
by the time elapsed after the initial event. In the acute 
phase, a hematoma is hyperdense, becoming more 
isodense in the chronic phase. On MRI, the intensity of 
a hematoma also changes over time. On T1-weighting, 
hematoma is hyperintense in the beginning, becoming 
more and more isointense in the chronic phase. On 
T2-weighting, a hematoma starts as hyperintense 
and resolves in the chronic phase with zones devoid 
of signal (visualized as black space) due to deposition 
of hemosiderin, and which occurs mostly in the 
periphery[18] (Figures 1 and 2). 
Data collection for analysis
HCA subtyping - for steatotic, inflammatory, β-catenin-
positive and unclassified HCA - was determined based 
on findings of immunohistochemistry or of the typical 
MRI features[19-21]. In cases that the HCA subtype was 
not able to be established by MRI or biopsy, previous 
available MRI scans were reviewed by an experienced 
radiologist.
Medical records were reviewed to collect each 
patient’s demographic features, clinical presentation, 
tumor features, initial and subsequent management 
(including surgery or intervention techniques), short- 
and long term complications and patient and lesion 
follow-up. If patients had been referred to our center 
by another hospital, we requested the data from the 
referring hospital, with consent of the patient. 
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Figure 1  Representative case of grade Ⅱ bleeding hepatocellular adenoma involving a 23-year-old female who presented at the emergency department 
with an acute hematoma in the right liver lobe. A: Computed tomography without intravenous contrast shows a hyperdense fluid collection in the liver (triangle); B: 
Some months later after conservative treatment, the collection appeared hyperintense on T2-weighting, with a hemosiderin ring surrounding the collection (arrow); C: 
At the same time, the collection appeared hyperintense on T1-weighting.
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The subtype was not defined in all other patients. 
Initial presentation and treatment
In all 23 patients, hemorrhage was the first pre-
sentation, and none of the patients were diagnosed 
as having HCA before the bleeding. Fifteen out of 
the 23 patients (65.2%) were hemodynamically 
stable at presentation, and one patient presented 
with hypovolemic shock. A total of 13 patients 
(56.5%) were treated conservatively. Nine patients 
(39.1%) underwent SAE in the acute phase, and 
one of them also underwent an acute resection due 
to persistent bleeding after the SAE. One patient 
underwent ultrasound-guided drainage of a presumed 
liver abscess, through which massive bleeding was 
found. Additional imaging for this patient showed an 
undetermined liver tumor, which prompted the patient 
referral to our hospital, where we confirmed the tumor 
to be an HCA. 
Comparison of the patients initially treated con-
servatively to those treated with intervention showed 
no statistically significant differences for age, median 
HCA diameter, median follow-up time, median hospital 
stay nor median hemoglobin level at presentation. 
However, the intervention group showed a statistically 
greater reduction in median hemoglobin level on day 
0-3 compared to the conservative treatment group 
(0.9 mmol/L vs 2.4 mmol/L respectively, P = 0.006) 
Statistical analysis
All statistical analyses were performed using SPSS 
software, version 21.0 (IBM, Armonk, NY, United 
States). All non-normal distributed variables were 
summarized as median and interquartile range (IQR); 
binary variables were summarized as frequency (n). 
Differences between groups were investigated using 
the Mann-Whitney U test for continuous variables. A 
P value of < 0.05 was considered as the threshold for 
significance. 
RESULTS
Study population and case characteristics
We assessed 23 consecutive patients who were 
admitted to hospital for massive intrahepatic hemorr-
hage or hemoperitoneum due to ruptured HCA (Table 
1). All patients were female, with a median age 
of 34-years-old (IQR: 30-44 years). Fifteen of the 
patients presented with grade Ⅱ hemorrhage, and 8 
with grade Ⅲ hemorrhage. The median lesion size was 
76 mm (IQR: 55-92 mm), with 14/23 (60.8%) located 
in the right or left lateral liver and the remaining 9/23 
(39.1%) located in the right medial or central liver 
(Table 2). Nineteen out of the 23 patients (82.6%) 
used OCs at the time of presentation. Two patients had 
an I-HCA, and a third patient had both an I-HCA as well 
as a H-HCA (steatotic), of which the I-HCA ruptured. 
A B
C
Figure 2  Representative case of grade Ⅲ bleeding hepatocellular adenoma involving a 28-year-old female who presented at the emergency department. 
A: Coronal computed tomography (CT) image in arterial phase shows a large hematoma in the left liver lobe (arrow); B: On the axial CT slice different bleeding 
adenomas are present in both lobes (arrows). Extracapsular peritoneal bleeding around the stomach is seen (triangle); C: One year later on magnetic resonance 
imaging in the venous phase all adenomas have decreased significantly in size. 
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(Table 2).
Short-term complications
Of the 23 patients, 4 (17.4%) suffered severe 
short-term complications (Table 1). In 2 patients, 
abscesses developed after embolization or resection, 
necessitating additional percutaneous drainage and 
resulting in hospital stays of 33 and 40 d respectively. 
One patient suffered acute liver failure after SAE, 
affecting both the left and right hepatic artery, with 
laboratory tests showing increases in aspartate 
transaminase (350-fold), alanine transaminase 
(170-fold), bilirubin (5.4-fold), lactate (4.5-fold) and 
the international normalized ratio (INR; 1.8-fold). 
Spontaneous recovery occurred within 5 d, and the 
total duration of hospital stay for this patient was 22 d. 
The patient who presented with major hypovolemic 
shock was treated conservatively and suffered major 
hemoperitoneum, resulting in respiratory insufficiency, 
kidney failure and abdominal compartment syndrome. 
This was a patient who had recent history of oral 
anticoagulants for treatment of deep vein thrombosis. 
Initially, her case was classified as venous hemorrhage 
due to an excessively high INR, and therefore she 
was treated conservatively. After recovery, she was 
referred to our hospital and the diagnosis of HCA was 
only made upon liver imaging after the hematoma had 
become, more or less, absorbed. The total duration of 
hospital stay for this patient was 61 d.  
Elective treatment and follow-up
Median follow-up time was 36 mo (IQR: 15-79 mo). 
One patient underwent elective resection, 1 underwent 
elective SAE and 2 underwent elective radiofrequency 
ablation (RFA) to address residual HCA (Table 3). 
These patients either had residual HCA of > 5 cm in 
size or a smaller lesion but with an expressed desire 
for future pregnancy. Out of the total 23 patients in 
Table 1  Clinical features at presentation
Case no. Age (yr) OC use Type of 
bleeding, grade
Initial 
management
ICU Blood 
products
Hospital stay 
(d)
Short-term complications
Initially conservatively treated
   1 49 Yes Ⅱ Cons. No No 19 -
   2 43 Yes Ⅲ Cons. Yes Yes   7 -
   3 30 Yes Ⅱ Cons. No No   7 -
   4 36 No Ⅱ Cons. No No 19 -
Stopped 12 mo 
prior to bleeding
   5 33 Yes Ⅱ Cons. No No   8 -
   6 23 Yes Ⅱ Cons. Yes Yes 28 -
   7 30 Yes Ⅱ Cons. No No 12 -
   8 39 Yes Ⅱ Cons. No No   9 -
   9 43 Yes Ⅲ Cons. No Yes 14 -
   10 44 Yes Ⅱ Cons. No No 13 -
   11 49 Yes Ⅲ Cons. Yes Yes 61 Hypovolemic shock, respiratory 
insufficiency, kidney failure, 
abdominal compartment 
syndrome
   12 31 Yes Ⅱ Cons. No No 10 -
   13 33 Yes Ⅲ Cons. No No 13 -
Initially treated with intervention
   14 22 Unknown Ⅲ SAE + 
resection
No Yes 40 Postoperative abdominal abscess, 
drainage pleural effusion
   15 33 No Ⅲ SAE Yes Yes Unknown -
Stopped 18 mo 
prior to bleeding
   16 24 Yes Ⅲ SAE Yes Yes 18 -
   17 36 Yes Ⅱ SAE Yes No 22 Acute liver failure after SAE left 
and right hepatic artery
   18 48 Yes Ⅱ SAE No No 10 -
   19 48 Yes Ⅲ SAE Yes No   6 -
   20 34 No Unknown SAE Unknown Unknown Unknown -
Stopped 7 mo 
prior to bleeding
   21 30 Yes Ⅱ US-guided 
drainage
No No 10 -
   22 56 Yes Ⅱ SAE Yes No Unknown -
   23 20 Yes Ⅲ SAE No Yes 33 Rebleed after 3 mo, drainage 
hepatic abscess, drainage pleural 
effusion
ICU: Intensive care unit; OC: Oral contraceptive; SAE: Selective arterial embolization; US: Ultrasound.
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the study, 18 (78.3%) were kept under surveillance 
for > 6 mo, all showing regression of the tumor from 
a median diameter of 76 mm (IQR: 55-92 mm) to 25 
mm (IQR: 17.3-41.5 mm). 
Rebleeding was reported in one patient (4.3%), 
which occurred 3 mo after the initial hemorrhage. This 
was the only patient in whom OC was continued after 
the first bleeding because the underlying etiology of 
the hemorrhage had not yet been established. After 
the rebleeding, the patient was referred to our tertiary 
center and the diagnosis of HCA was made. The 
rebleeding was also managed with a wait-and-watch 
policy, and cessation of OC lead to regression of the 
HCA. 
None of the patients in this study had long-term 
complications. Out of the 9 patients who did not have 
any treatment (initial or elective), 2 became pregnant. 
In the first patient, the HCA showed growth from 46 
mm to 65 mm, but no hemorrhage occurred during 
pregnancy and after the delivery the HCA regressed. 
In the second patient, the lesion remained stable in 
size (30 mm) throughout the pregnancy. 
DISCUSSION
In this retrospective cohort study, we evaluated 
the outcome of acute management of patients with 
massive hemorrhage due to ruptured HCA and 
confirmed that a conservative approach is justified 
in the acute situation if there is a hemodynamically 
stable condition. In the case of persistent bleeding, 
SAE can be a solution. Our cohort showed a significant 
difference in median decrease in hemoglobin level 
when the conservatively-treated group was compared 
to the group of patients who underwent initial 
intervention, with a greater decrease (median: 2.4 
mmol/L) occurring in the intervention group. Four 
patients in our study suffered the following severe 
short-term complications: 1 patient who had used oral 
anticoagulants and then presented with hypovolemic 
shock developed respiratory insufficiency, kidney 
failure and abdominal compartment syndrome; 2 
patients who developed complications after SAE; and 
1 patient who developed postoperative complications 
after both SAE and resection in the acute phase. All 
complications resulted in longer hospital stay; however, 
no long-term complications were documented. 
After a median follow-up time of 36 mo, all tumors 
under surveillance showed spontaneous regression, with 
a median size decrease from 76 mm at presentation to 
25 mm at last follow-up. This finding is comparable to 
the regression reported for non-hemorrhagic HCA after 
OC discontinuation[10,11]. Only 1 case of rebleeding was 
reported (4.3%) in a patient who did not discontinue 
OC, and this occurred at 3 mo after the initial bleed. 
Secondary treatment, such as elective tumor resection, 
SAE or RFA, was only performed in patients with HCA 
> 5 cm in size after follow-up and/or in patients with an 
expressed desire for future pregnancy. 
This study, however, did not establish whether 
hemorrhagic HCA should remain in regular follow-up or 
when, if ever, it will be safe to end surveillance. Most 
lesions are > 5 cm at the moment of hemorrhage, 
causing at least a part of the vital adenoma tissue 
to become necrotic. Therefore, we are unsure if the 
higher risk of malignant degeneration in HCA > 5 cm 
is still present in hemorrhagic HCA; indeed, it might be 
advisable to keep these patients in regular follow-up. 
It is important to establish an optimal treatment 
plan for patients with ruptured HCA, as hemorrhage 
is a frequent complication of lesions > 5 cm[7]. In 
2006, Erdogan et al[14] conducted a study assessing 
management and outcome in patients treated for 
ruptured HCA, in which they compared laparotomy 
and gauze packing with observation. Their results 
suggested that stable patients could be treated 
conservatively and that resection of the HCA in the 
acute situation is accompanied by a higher morbidity. 
With the advent of SAE a decade ago, Stoot et al[16] 
conducted a small cohort study including 11 patients, 
which established the safety and efficacy of SAE for 
the treatment of ruptured HCA. Recently, the European 
Association for Study of the Liver issued a European 
clinical practice guideline for the management of 
Table 2  Demographics and features of patients treated conservatively or with intervention
Initial conservative, n  = 13 Initial intervention, n  = 10 Total, n  = 23 P value
Median age (yr) 36 (30.5-43.5) 33.5 (23.5-48.0) 34 (30-44) 0.563
Median HCA diameter at 
diagnosis (mm)
76 (55-101.5) 76.5 (51.3-92.5) 76 (55-92) 0.648
Median follow-up time (mo) 66 (23-87) 22.5 (12.8-60.3) 36 (15-79) 0.257
Type of bleeding 0.349
   Grade Ⅱ 9 5 15
   Grade Ⅲ 4 5   8
Median hospital stay (d) 13 (8.5-19) 18 (10-33) 13 (9.3-21.3) 0.588
Median Hb level at 
presentation (mmol/L)
8.0 (6.0-8.4) 7.5 (7.0-8.0) 7.6 (7.0-8.1) 0.710
Median decrease Hb day 0-3 
(mmol/L)
0.9 (0-1.7) 2.4 (1.6-3.5) 1.6 (0.4-2.4)  0.0061
1Statistically significant. Values are given as median (IQR). 
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benign liver tumors[13]. In this guideline, patients 
with massive hemorrhage due to ruptured HCA are 
recommended to be transferred to a center with an 
interventional radiology department and the possibility 
to perform SAE. 
To the best of our knowledge, this study presented 
herein is the first to assess outcome and risk of 
rebleeding in patients with massive hemorrhage due to 
ruptured HCA. Unfortunately, for most of the included 
patients, the HCA subtype remained unknown. This is 
most likely the result of the hemorrhage itself, which 
makes it very difficult to distinguish HCA subtypes 
according to imaging characteristics. As we only 
knew the subtype for 3 of the patients in our study 
population (all I-HCA), we cannot make a judgement 
about the distribution of the various subtypes and 
the relationship to the different variables. Previous 
studies have shown that the risk for hemorrhage is 
the greatest in I-HCA[8], which was confirmed in our 
population.  
It was noticed that in our study 60.8% of the 
ruptured HCA were located in the right or left lateral 
liver, and the remaining 39.1% were located medial or 
central. This does not entirely correspond to the study 
by Bieze et al[8] that was conducted in 2014, in which 
those authors identified HCA located in the left lateral 
liver as a risk factor for hemorrhage. It is thought 
that the medial or central location and maximum 
surrounding liver tissue prevent rupture of the HCA by 
tamponade. Our study likewise suggests that medial or 
centrally located HCA may cause hemorrhage as well. 
The biggest limitation of this retrospective study 
is the design, which has inherent bias. By requesting 
data from all of the treatment hospitals, the proportion 
of missing data was kept to a minimum. In addition, 
hemorrhage makes the measurement of HCA 
diameter more difficult and less reliable. Therefore, the 
reported median diameter of 76 mm for the HCAs at 
presentation might be an overestimation.
In conclusion, this study confirmed that patients 
with massive hemorrhage due to ruptured HCA but 
with cessation of bleeding and in stable condition may 
be treated conservatively in the acute situation. SAE 
can be a solution for unstable patients with persistent 
bleeding and decreasing hemoglobin levels. No long-
term complications were documented. As the risk of 
rebleeding is very low after cessation of OC and most 
HCAs regress spontaneously, secondary treatments, 
such as tumor resection, SAE or RFA, may only be 
considered in patients with HCA > 5 cm after follow-
up or in patients with an expressed desire for future 
pregnancy. However, regular follow-up by imaging in 
these patients should be considered.
COMMENTS
Background
Hepatocellular adenoma (HCA) is a rare benign liver tumor that may present 
with spontaneous massive hemorrhage.
Research frontiers
This study provides unique insights into the outcome of acute management 
of these patients and the sequelae of massive bleeding, including risk of 
rebleeding and need for elective tumor resection. 
Innovations and breakthroughs
To the best of our knowledge, this is the first study assessing the outcome and 
the sequelae of massive bleeding, including the risk of rebleeding and need for 
Table 3  Tumor features and follow-up
Case no. Diameter HCA 
at diagnosis 
(mm)
Location of 
HCA
Elective 
treatment of 
HCA
Last known 
HCA diameter 
(mm)
Initially conservatively treated
1 200 Right lateral 
(sVI/VII)
Surveillance   6
2   76 Right lateral 
(sVI/VII)
Surveillance 22
3   60 Right lateral 
(sVI)
Surveillance 26
4   80 Right medial 
(sVIII)
Surveillance 53
5   80 Right lateral 
(sVI)
Resection -
6   75 Right lateral 
(sVI/VII)
RFA   0
7   75 Right lateral 
(sVI/VII)
Surveillance   8
8 143 Right medial 
(sVIII)
Surveillance 35
9   45 Right medial 
(sV/VIII)
Surveillance 40
10   39 Right lateral 
(sVII)
Surveillance 18
11   50 Right medial 
(sV)
Surveillance 21
12   92 Right lateral 
(sVI/VII)
Surveillance 43
13 111 Left lateral 
(sII/III)
Surveillance 92
Initially treated with intervention
14   90 Central 
(sIV/VIII)
No adenoma 
tissue after 
resection
-
15   55 Right medial 
(sVIII)
Surveillance 20
16   40 Right medial 
(sV/VIII)
RFA   0
17   73 Central 
(sIV/VIII)
Surveillance 40
18   80 Right lateral 
(sVI/VIII)
Surveillance 24
19 100 Left lateral 
(sII/III)
Surveillance 45
20 100 Central 
(sIV/V/VIII)
SAE 42
21   55 Right lateral 
(sVII)
Surveillance 38
22   25 Left lateral 
(sIII)
Surveillance 17
23   87 Right lateral 
(sVII)
Surveillance 62
RFA: Radiofrequency ablation; s: Liver segment; SAE: Selective arterial 
embolization. HCA: Hepatocellular adenoma.
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elective tumor resection, in this patient population. As massive bleeding due to 
ruptured HCA is rare, we present a unique series of 23 cases. 
Applications
This study confirms that patients with massive hemorrhage due to ruptured 
HCA, but with cessation of bleeding and in stable condition, may be treated 
conservatively in the acute situation. Embolization can be a solution for 
unstable patients with persistent bleeding and decreasing hemoglobin levels. 
As the risk of rebleeding is very low after cessation of OC and most HCAs 
regress spontaneously, secondary treatment may only be considered in patients 
with HCA > 5 cm after follow-up or in patients with an expressed desire for 
pregnancy. However, regular follow-up by imaging in these patients should be 
considered.
Terminology
HCA is a rare benign liver tumor related to use of estrogen-containing oral 
contraceptives, and which may present with spontaneous massive hemorrhage.
Peer-review
This is an interesting clinically relevant study. It is well conducted and well 
written. The outcome is useful in the clinical management of HCA.
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